Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL560398

N.N.O=C(O)/C(CC(O)(Cc1c[nH]c2ccccc12)C(=O)O)=N/O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.48
MEN1 O00255 6/20 0.48
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
SLC6A2 P23975 1/20 0.43
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
LMNA P02545 2/20 0.42
APAF1 O14727 1/20 0.42
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MPO P05164 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL560495 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL4811413 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL3445835 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL4811403 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL4811423 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL560400 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
Ammonia Solution, Strong SCHEMBL560399 1.00 KMT2A (0.48) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL13844616 0.99 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL560222 0.99 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL559736 0.99 KMT2A (0.49) KMT2AMEN1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806408-B1 Process for producing amino acid derivatives from hydroxyimino acids AJINOMOTO KK (JP) 2012-04-18 EP disclosed
US-20120035373-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC (JP) 2012-02-09 US disclosed
US-8043836-B2 Contacting Citrobacter/Escherichia and/or enzyme with a hydroxyimino acid; for biosynthesis of tryptophan AJINOMOTO CO., INC. (JP) 2011-10-25 US disclosed
US-7868187-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2011-01-11 US disclosed
US-7816541-B2 Process for producing an optically active compound AJINOMOTO CO., INC. (JP) 2010-10-19 US disclosed
US-20100105924-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC. (JP) 2010-04-29 US disclosed
US-7678925-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2010-03-16 US disclosed
US-20090259052-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC (JP) 2009-10-15 US disclosed
US-20080207920-A1 PROCESS FOR PRODUCING AN OPTICALLY ACTIVE COMPOUND AJINOMOTO CO., INC. (JP) 2008-08-28 US disclosed
US-20080193984-A1 Process For Producing Amino Acid Derivative From Hydroxyimino Acid AJINOMOTO CO., INC. (JP) 2008-08-14 US disclosed
EP-1956003-A2 Process for producing an optically active compound Ajinomoto Co., Inc. (JP) 2008-08-13 EP disclosed
US-7390909-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2008-06-24 US disclosed
US-20080091032-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES AJINOMOTO CO. INC (JP) 2008-04-17 US disclosed
EP-1806408-A1 PROCESS FOR PRODUCING AMINO ACID DERIVATIVE FROM HYDROXYIMINO ACID Ajinomoto Co., Inc. (JP) 2007-07-11 EP disclosed
US-7064219-B2 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO., INC. (JP) 2006-06-20 US disclosed
US-20060074249-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO. INC (JP) 2006-04-06 US disclosed
US-20050004394-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes AJINOMOTO CO. IN (JP) 2005-01-06 US disclosed
EP-1466890-A1 PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES Ajinomoto Co., Inc. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207920-A1 PROCESS FOR PRODUCING AN OPTICALLY ACTIVE COMPOUND AADAT, ALDOA, ALAD KMT2A 2106/4885MEN1 1204/4885MAPT 622/4885
US-20120035373-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20050004394-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20080091032-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20100105924-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20060074249-A1 Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885
US-20090259052-A1 PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES GLUL, MON2, GRIK5 KMT2A 1562/4885MEN1 62/4885MAPT 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.